Patents Represented by Attorney, Agent or Law Firm Janelle D. Strode
  • Patent number: 6706670
    Abstract: This invention relates to novel water soluble metal working fluid compositions, their use to work metal, a process for working metal using such compositions and the metal worked article of manufacture. More particularly, this invention relates to fluid compositions useful in cutting, grinding, shaping and other metal working operations which require a lubricant. The terms “first Group A” and “second Group B” are used herein to denote different groups and not to indicate any sequence of use or selection as any possible combination or sequence of use of a component(s) is envisioned without limit of any kind. The disclosed fluid compositions are also anticorrosive and environmentally more acceptable than current oil based fluids.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: March 16, 2004
    Assignee: Solutia, Inc.
    Inventors: Dennis J. Kalota, Yueting Chou, Timothy K. Hirzel, David C. Silverman, Jacob S. Tou, Winsor R. Cho
  • Patent number: 6639076
    Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: October 28, 2003
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
  • Patent number: 6329342
    Abstract: The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: December 11, 2001
    Assignee: Eli Lilly and Company
    Inventors: Raymond F. Kauffman, Alan D. Palkowitz
  • Patent number: 6162927
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: August 4, 1997
    Date of Patent: December 19, 2000
    Assignee: Abbott Laboratories
    Inventors: Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
  • Patent number: 6124341
    Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
    Type: Grant
    Filed: May 29, 1998
    Date of Patent: September 26, 2000
    Assignee: Abbott Laboratories
    Inventors: Andrew S. Tasker, Martin Winn, Steven A. Boyd, Hwan-Soo Jae, Thomas W. von Geldern, Bryan K. Sorensen, Kenneth J. Henry
  • Patent number: 6110922
    Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: August 29, 2000
    Assignee: Abbott Laboratories
    Inventors: James Link, Gang Liu, Zhonghua Pei, Tom von Geldern, Martin Winn, Zhili Xin
  • Patent number: 6017928
    Abstract: A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: January 25, 2000
    Assignee: Abbott Laboratories
    Inventors: Dale J. Kempf, Daniel W. Norbeck, Hing Leung Sham, Chen Zhao, Thomas J. Sowin, Daniel S. Reno, Anthony R. Haight
  • Patent number: 6013674
    Abstract: This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.
    Type: Grant
    Filed: May 1, 1998
    Date of Patent: January 11, 2000
    Assignee: Eli Lilly and Company
    Inventors: John Michael Morin, Jr., Michael Dean Kinnick, Robert Theodore Vasileff, William Thomas Jackson
  • Patent number: 5976813
    Abstract: Continuous format high throughput screening (CF-HTS) using at least one porous matrix allows the pharmaceutical industry to simultaneously screen large numbers of chemical entities for a wide range of biological or biochemical activity. In addition, CF-HTS is useful to perform multi-step assays.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: November 2, 1999
    Assignee: Abbott Laboratories
    Inventors: Bruce A. Beutel, Mark E. Schurdak, Martin J. Voorbach, David J. Burns, Mary K. Joseph
  • Patent number: 5919946
    Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Neel
  • Patent number: 5916916
    Abstract: The instant invention provides a series of naphthyl compounds having an oxygen linker at the 1-position which are useful as selective estrogen receptor modulators.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: June 29, 1999
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Alan David Palkowitz
  • Patent number: 5917038
    Abstract: The present invention relates to a process for preparing acrylamides; wherein, a propiolamide is reacted with an activated aromatic ring to yield a wide variety of acrylamides.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: June 29, 1999
    Assignee: Eli Lilly and Company
    Inventors: Lynne Ann Hay, David Mitchell
  • Patent number: 5889000
    Abstract: The invention provides naphthofluorene compounds, intermediates, formulations, processes, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions, including hyperlipidemia, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: March 30, 1999
    Assignee: Eli Lilly and Company
    Inventors: Henry Uhlman Bryant, Jeffrey Alan Dodge, Charles Willis Lugar, III
  • Patent number: 5859261
    Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: January 12, 1999
    Assignee: Eli Lilly and Company
    Inventors: Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Andrew Neel
  • Patent number: 5856341
    Abstract: The invention provides benzo?b!indenothiophene compounds of formula I ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are as defined in the specification, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: January 5, 1999
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
  • Patent number: 5852193
    Abstract: The invention relates to intermediates and processes for producing benzothiophenes employing hydroxylamines.
    Type: Grant
    Filed: April 29, 1998
    Date of Patent: December 22, 1998
    Assignee: Eli Lilly and Company
    Inventor: Erik Christopher Chelius
  • Patent number: 5843963
    Abstract: The invention provides benzothiophene compounds, of formula I, ##STR1## wherein R1, R2, R3, R4 and n are as defined in the specification, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions, including hyperlipidemia, and other cardiovascular pathologies.
    Type: Grant
    Filed: September 19, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: Kenneth Lee Hauser, Alan David Palkowitz, Kenneth Jeff Thrasher
  • Patent number: 5843940
    Abstract: The invention provides benzothiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia, and estrogen-dependent cancer.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: George Joseph Cullinan, Brian Stephen Muehl
  • Patent number: 5843976
    Abstract: The present invention provides novel methods of lowering serum cholesterol and inhibiting smoother muscle cell proliferation, particularly restenosis, in humans, and inhibiting uterine fibroid disease and endometriosis in women comprising administering to a human/woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo, or trifluoromethyl;R.sup.1 and R.sup.2 each are the same or different C.sub.1 -C.sub.6 alkyl group;n is an integer from 2 to 6; andR.sup.3 and R.sup.4 each are independently C.sub.1 -C.sub.4 alkyl, or combine to form a substituent selected from the group consisting of pyrrolidino, morpholino, piperidino, piperazino, 4-(C.sub.1 -C.sub.6 alkyl)piperazino, and 4-phenyl-piperazino; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, Jeffrey A. Dodge
  • Patent number: 5843965
    Abstract: The instant invention provides novel benzo?b!thiophene compounds, intermediates, compositions, pharmaceutical formulations, and methods of use for the inhibition of bone loss or bone resorption and for treatment of cardiovascular-related pathological conditions.
    Type: Grant
    Filed: August 27, 1997
    Date of Patent: December 1, 1998
    Assignee: Eli Lilly and Company
    Inventor: Alan David Palkowitz